Skip to main navigation Skip to search Skip to main content

IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes

  • Emily K. Sims
  • , David Cuthbertson
  • , Lauric A. Ferrat
  • , Emanuele Bosi
  • , Carmella Evans-Molina
  • , Linda A. DiMeglio
  • , Brandon M. Nathan
  • , Heba M. Ismail
  • , Laura M. Jacobsen
  • , Maria J. Redondo
  • , Richard A. Oram
  • , Jay M. Sosenko

Research output: Contribution to journal › Article › peer-review

Abstract

Aims/hypothesis: Accurate understanding of type 1 diabetes risk is critical for optimisation of counselling, monitoring and interventions, yet even within established staging classifications, individual time to clinical disease varies. Previous work has associated IA-2A positivity with increased type 1 diabetes progression but a comprehensive assessment of the impact of screening for IA-2A positivity across the natural history of autoantibody positivity has not been performed. We asked whether IA-2A would consistently be associated with higher risk of progression within and across established stages of type 1 diabetes in a large natural history study. Methods: Genetic, autoantibody and metabolic data from adult and paediatric autoantibody-negative (n=192) and autoantibody-positive (n=4577) relatives of individuals with type 1 diabetes followed longitudinally in the Type 1 Diabetes TrialNet Pathway to Prevention Study were analysed. Cox regression was used to compare cumulative incidences of clinical diabetes by autoantibody profiles and disease stages. Results: Compared with IA-2A− individuals, IA-2A+ individuals had higher genetic risk scores and clinical progression risk within single-autoantibody-positive (5.3-fold increased 5 year risk), stage 1 (2.2-fold increased 5 year risk) and stage 2 (1.3-fold increased 5 year risk) type 1 diabetes categories. Individuals with single-autoantibody positivity for IA-2A showed increased metabolic dysfunction and diabetes progression compared with people who were autoantibody negative, those positive for another single autoantibody, and IA-2A− stage 1 individuals. Individuals at highest risk within the single-IA-2A+ category included children (HR 14.2 [95% CI 1.9, 103.1], p=0.009), individuals with IA-2A titres above the median (HR 3.5 [95% CI 1.9, 6.6], p<0.001), individuals with high genetic risk scores (HR 1.4 [95% CI 1.2,1.6], p<0.001) and individuals with HLA DR4-positive status (HR 3.7 [95% CI 1.6, 8.3], p=0.002). When considering all autoantibody-positive individuals, progression risk was similar for euglycaemic IA-2A+ individuals and dysglycaemic IA-2A− individuals. Conclusions/interpretation: IA-2A positivity is consistently associated with increased progression risk throughout the natural history of type 1 diabetes development. Individuals with single-autoantibody positivity for IA-2A have a greater risk of disease progression than those who meet stage 1 criteria but who are IA-2A−. Approaches to incorporate IA-2A+ status into monitoring strategies for autoantibody-positive individuals should be considered.

Original languageEnglish (US)
Pages (from-to)993-1004
Number of pages12
JournalDiabetologia
Volume68
Issue number5
DOIs
StatePublished - May 2025

Bibliographical note

Publisher Copyright:
© The Author(s) 2025.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Autoantibodies
  • IA-2A
  • Islet antigen-2
  • Precision medicine
  • Prediction
  • Progression
  • Stratification
  • Type 1 diabetes

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes'. Together they form a unique fingerprint.

Cite this